Septerna Inc
Research Septerna Inc (SEPN) on Bullrun: market cap USD 1.72B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSEPN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.72B
- Financial periodQ2 2026
- RevenueUSD 26.75M
- Net income-USD 13.03M
- Free cash flow-USD 22.18M
Valuation Snapshot
latest market cap is USD 1.72B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 45.95M | -USD 48.88M | USD 109.67M | n/a | -1.1 | USD 120.72M | USD 23.63M | USD 381.93M |
| FY2024 | USD 1.08M | -USD 71.80M | -USD 69.57M | n/a | -7.26 | USD 238.20M | USD 25.48M | USD 420.05M |
| FY2023 | USD 151.00K | USD 4.18M | -USD 41.60M | n/a | 0.29 | USD 88.48M | USD 12.57M | -USD 38.37M |
| FY2022 | USD 0 | -USD 27.68M | -USD 24.59M | n/a | -1.42 | USD 30.61M | USD 710.00K | -USD 44.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 1.72B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.25B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.02B | n/a | n/a | n/a |
About Septerna Inc
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Septerna Inc's market cap?
Septerna Inc's market capitalization is USD 1.72B.
What does Septerna Inc do?
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.